.jpeg)
Reviewed and updated 20 August 2026 against Genetic Alliance UK, the England Rare Diseases Action Plan 2026 and current MHRA policy.
By Aneeta Prem MBE
Rare Disease Day 2026 focused on one word: equity.
That is a useful standard because rare conditions are individually uncommon but collectively affect millions of people. Genetic Alliance UK says more than 3.5 million people in the UK live with a rare condition.
Equity does not mean giving every patient an identical pathway. It means making sure rarity itself does not become a reason for poorer access to diagnosis, specialist care, treatment or support.
What Rare Disease Day is
Rare Disease Day is a global patient-led campaign coordinated internationally by EURORDIS-Rare Diseases Europe. In the UK, Rare Disease UK, the national campaign run by Genetic Alliance UK, leads activity.
It is held on the last day of February — 28 February in most years and 29 February in leap years.
For 2026, Genetic Alliance UK used the theme Equity for Rare and published work on what fair healthcare should mean for people with rare and undiagnosed conditions.
Why rare does not mean marginal
UK policy defines a rare condition as one affecting fewer than 1 in 2,000 people.
There are thousands of different rare conditions. Taken together, around 1 in 17 people in the UK will be affected by a rare condition at some point in their lives.
The challenge is that healthcare systems are usually organised around conditions seen more frequently. Rare conditions can therefore expose weaknesses in professional awareness, referral routes, evidence, specialist capacity and care co-ordination.
The England Rare Diseases Action Plan 2026 continues four national priorities: faster diagnosis, increased awareness among healthcare professionals, better co-ordination of care and improved access to specialist care, treatment and drugs.
Treatment inequality remains real
In May 2026, the Medicines and Healthcare products Regulatory Agency said fewer than 5% of rare diseases currently have an approved treatment.
The regulator launched work on a new framework intended to make development and licensing of therapies for very small patient populations more workable while maintaining patient safety.
That matters because equity is not achieved simply by diagnosing a condition. People also need meaningful options after diagnosis: treatment where one exists, symptom management where it does not, co-ordinated care and honest information about uncertainty.
What the zebra idea is trying to say
Zebra imagery is widely used across rare-disease communities as a reminder that clinicians sometimes need to consider an uncommon explanation when the common explanation no longer fits.
It is a useful metaphor, but it should not be turned into a medical rule.
Good diagnosis still starts with evidence, history, examination and appropriate investigation. The lesson is not “assume rare”. It is do not stop thinking when the expected explanation fails to account for the patient’s symptoms.
Where trigeminal neuralgia fits
Trigeminal neuralgia is a neurological facial-pain condition capable of causing sudden, severe attacks of pain. Ordinary actions such as eating, speaking, brushing the teeth, touching the face or exposure to cold air can trigger attacks for some people.
I live with bilateral trigeminal neuralgia and, as Chief Executive of TNA UK, work from a patient and charity-leadership perspective on awareness, patient experience, access to care and the wider impact of facial pain.
That perspective is not a substitute for clinical expertise. Its value is different: patients can show where pathways are confusing, where information is difficult to use, what treatment burden feels like in daily life and what questions service data should be able to answer.
Equity for TN should be measurable
For trigeminal neuralgia, equity should mean more than everybody being entitled to NHS care in principle.
Useful questions include:
- Are patients recognised and referred consistently when symptoms fit TN?
- Are dental and neurological pathways joined up well enough to reduce unnecessary delay?
- Can patients obtain specialist advice when first-line treatment is ineffective or poorly tolerated?
- Is imaging available when clinically indicated?
- Are geographical differences in pathway times measured?
- Are quality of life and treatment burden taken seriously alongside pain frequency?
Some of those questions cannot currently be answered from a single public TN-specific national dataset. That is itself an important evidence gap.
Equity is not the same as identical care
A rare condition may require expertise concentrated in specialist centres. That does not mean every hospital should provide every specialist intervention.
Equity means the route into appropriate expertise should be clear and fair, regardless of whether the expertise itself is local.
It also means reasonable adjustments where disability, communication needs, employment, caring responsibilities or travel make access harder.
Patient voice belongs in rare-disease policy
The rare-disease agenda increasingly recognises that lived experience is evidence about how systems operate.
Patient voice should not be used to replace clinical trials, epidemiology or service data. It should help identify the outcomes and barriers those systems need to measure.
That distinction is especially important in rare conditions, where small populations can make every evidence source valuable but also easy to overinterpret.
Final word
Rare Disease Day is useful if it leaves behind more than awareness.
For 2026, the challenge is equity: faster recognition, clearer pathways, fair access to specialist care, better treatment development and evidence that tells us where people are being left behind.
Rare should describe the condition. It should not describe the quality of care.
Sources and further reading
- Genetic Alliance UK: Rare Disease Day 2026
- Department of Health and Social Care: England Rare Diseases Action Plan 2026
- MHRA: rare-disease therapies framework
- NHS: trigeminal neuralgia
